Suvaxyn PCV
adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets
Table of contents
Overview
The marketing authorisation for Suvaxyn PCV has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Suvaxyn PCV
|
| Agency product number |
EMEA/V/C/000149
|
| Active substance |
porcine circovirus recombinant virus (CPCV) 1-2, inactivated
|
| International non-proprietary name (INN) or common name |
adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets
|
| Species |
Pigs (piglets)
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA07
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
13
|
| Date of issue of marketing authorisation valid throughout the European Union |
24/07/2009
|
| Contact address |
Rue Laid Burniat 1 |
Product information
08/04/2020 Suvaxyn PCV - EMEA/V/C/000149 - R/0028
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.